PROCEPT Biorobotics Corp (PRCT) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. PROCEPT Biorobotics Corporation is a surgical robotics company focused on urology, specifically developing the AquaBeam Robotic System for treating benign prostatic hyperplasia (BPH) via Aquablation therapy. As of June 30, 2024, the company had a global install base of 516 systems, including 400 in the United States.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Q2 2023 (3 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $53.4 million | $97.9 million | $33.1 million | $57.5 million |
| Gross Profit | $31.5 million | $56.5 million | $18.4 million | $30.9 million |
| Gross Margin | 59% | 58% | 56% | 54% |
| Net Loss | $(25.6) million | $(51.6) million | $(25.3) million | $(53.8) million |
| Net Loss Per Share | $(0.50) | $(1.01) | $(0.56) | $(1.19) |
| Cash & Equivalents | $214.1 million (as of June 30, 2024) | |||
| Long-Term Debt | $52.0 million (Principal outstanding) | |||
| Operating Cash Flow | $(48.0) million (YTD) | $(64.3) million (YTD) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 61% year-over-year for Q2 and 70% year-over-year for the six-month period. Growth was driven by a 99% increase in handpiece and consumable sales and a 27% increase in system sales and rentals for Q2.
- Margin Expansion: Gross margin improved to 59% in Q2 2024 from 56% in Q2 2023, attributed to higher unit sales spreading fixed manufacturing overhead and increased average selling prices.
- Expense Increases: Operating expenses rose significantly. R&D expenses increased 51% QoQ (3-month comparison) due to salaries and tooling. SG&A expenses increased 26% due to commercial expansion and stock-based compensation.
- Net Loss Reduction: While the company remains unprofitable, the net loss narrowed slightly on a year-to-date basis ($51.6M vs $53.8M in 2023) despite higher operating costs, aided by increased interest income.
Guidance, Outlook, and Risks
- Liquidity: Management believes existing cash ($214.1M) and anticipated revenue are sufficient to fund operations for at least the next 12 months.
- Debt Covenants: The company has a $52.0M term loan maturing in October 2027. It is currently in an interest-only period. Covenants require maintaining either $100M in available cash or meeting specific revenue/growth targets if cash falls below that threshold. The company currently maintains sufficient cash to avoid strict revenue covenants.
- Strategic Focus: Future growth depends on expanding the install base (targeting 860 high-volume U.S. hospitals), increasing system utilization, and securing favorable reimbursement from commercial payors.
- Risks: Key risks include dependence on third-party payor reimbursement, competition, the ability to scale manufacturing efficiently, and the impact of interest rate fluctuations on debt costs.
Investor Verification Checklist
- Reimbursement Status: Verify the status of commercial payor coverage decisions outside of Medicare, as this is critical for hospital adoption.
- Install Base Utilization: Monitor the rate of system utilization (procedures per system) to validate the recurring revenue model from handpieces.
- Debt Covenant Compliance: Confirm the company maintains the $100M cash threshold to avoid triggering revenue-based financial covenants.
- Stock-Based Compensation: Review the trajectory of stock-based compensation ($14.2M YTD 2024), which significantly impacts operating expenses and dilution.
- Inventory Levels: Assess inventory growth ($43.9M) relative to sales velocity to ensure no obsolescence risks.